Results 31 to 40 of about 2,220 (157)

Anemia, Polycythemia and Leukemia (1): molecular biology and functional interrelationships of hematologic disorders [PDF]

, 2010
In this communication we emphasize the interconnectedness of hematologic neoplasms and their developmental processes, as well as propose new diagnostic classifications for a variety of hematologic disorders.
Correa, Paulo N.; Correa, Alexandra N.
core  

Pure Erythroleukemia (Variant Acute Myeloid Leukemia-vAML-M6) with Deletion of Chromosome 20, Mainly Presenting as Late Erythroblasts, a Unique Case Report with Review of Literature [PDF]

Indian Journal of Hematology and Blood Transfusion, 2012
Acute erythroleukemia is characterized by a predominant immature erythroid population and accounts for approximately 2-5 % of all cases of acute leukemia. Two subtypes are recognized based on the presence or absence of a significant myeloid component: erythroleukemia and pure erythroid leukemia.
Javid, Rasool, Sajad, Geelani, , Khursheed, , Yasir, Mohd Suhail, Lone, Mohd, Shaban   +5 more
openaire   +2 more sources

Acute erythroblastic leukemia (di guglielmo's disease) as a terminating event in a very-long survivor (27 years) with Hodgkin's disease.

Haematologica, 1982
Mantovani G, Del Giacco G. S, MARONGIU, FRANCESCO, Tognella S, Carcassi U. E.   +4 more
openaire   +3 more sources

Human sporadic breast carcinoma histotypes driven by the Human Betaretrovirus homologous to Mouse Mammary Tumor Virus

International Journal of Cancer, Volume 157, Issue 2, Page 371-383, 15 July 2025.
What's new? While estrogens, obesity, and alcohol are recognized risk factors for breast cancer, a viral hypothesis has been suggested based on the murine model of Mouse Mammary Tumor Virus (MMTV)‐induced mammary tumors. This study analyzed sequences of the human homolog of MMTV across human breast carcinoma histotypes, detecting the virus in all types
Prospero Civita, Chiara Maria Mazzanti, Francesca Lessi, Caterina Marchiò, Cristian Scatena, Michele Menicagli, Matteo Ghilli, Manuela Roncella, Antonio Giuseppe Naccarato, Anna Sapino, Jacob Hochman, Mauro Pistello, Generoso Bevilacqua   +12 more
wiley   +1 more source

PREFERENTIAL NUCLEAR ACCUMULATION OF JAK2V617F IN CD34+ BUT NOT IN GRANULOCYTIC, MEGAKARYOCYTIC OR ERYTHROID CELLS OF PATIENTS WITH PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASIA.

, 2010
Recently, Dawson et al. identified a previously unrecognized nuclear role for JAK2 in the phosphorylation of the tyrosine 41 of the histone H3 with the exclusion of HP1a from chromatin and resulting in a disregulation of several JAK2-regulated genes such
Fabrizio Pane, Vincenzo Martinelli, Vitalyi Senyuk, Giuseppina Nucifora, Rinaldi, Ciro Roberto, Paola Rinaldi, Ciro R. Rinaldi, Marica Gemei, Fabio Formiggini, Nicola Esposito, Adele Alagia   +10 more
core   +1 more source

Verteporfin‐Mediated In Situ Nanovaccine Based on Local Conventional‐Dose Hypofractionated Radiotherapy Enhances Antitumor and Immunomodulatory Effect

Advanced Science, Volume 12, Issue 20, May 29, 2025.
Here gelatinase‐responsive methoxypolyethyleneglycol–PVGLIG–polycaprolactone (mPEG–PVGLIG–PCL) nanoparticles’ loading verteporfin (N@VP) is developed, enhancing radiotherapy via X‐ray‐triggered singlet oxygen generation. Combined with 2 Gy (gray, a radiation dose unit) irradiation, N@VP achieves antitumor efficacy comparable to 8 Gy, and also promotes ...
Zhifan Zhang, Lin Li, Yuchen Ge, Anni Chen, Shanchao Diao, Yueling Yang, Qianyue Chen, Yingling Zhou, Jie Shao, Fanyan Meng, Lixia Yu, Manman Tian, Xiaoping Qian, Zhaoyu Lin, Chen Xie, Baorui Liu, Rutian Li   +16 more
wiley   +1 more source

Inter‐Ethnic Differences in the Efficacy and Safety of Tyrosine Kinase Inhibitors Used in Oncology: Insights From Phase 3 Clinical Trials

Clinical and Translational Science, Volume 18, Issue 5, May 2025.
ABSTRACT Differences in the efficacy and safety of tyrosine kinase inhibitors (TKIs) have been observed across ethnic/ancestry subpopulations (previously reviewed to 2017). With an expanding number of TKIs approved since that time, an updated review of TKI response across ethnic/ancestry subpopulations in Phase 3 TKI clinical trials was conducted.
Nicki M. Kyriacou, Annette S. Gross, Andrew J. McLachlan   +2 more
wiley   +1 more source

Poster Sessions

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +2 more sources

Analyzing the role of ferroptosis in ribosome‐related bone marrow failure disorders: From pathophysiology to potential pharmacological exploitation

IUBMB Life, Volume 76, Issue 12, Page 1011-1034, December 2024.
Abstract Within the last decade, the scientific community has witnessed the importance of ferroptosis as a novel cascade of molecular events leading to cellular decisions of death distinct from apoptosis and other known forms of cell death. Notably, such non‐ apoptotic and iron‐dependent regulated cell death has been found to be intricately linked to ...
Aliki Papadimitriou‐Tsantarliotou, Chrysostomos Avgeros, Maria Konstantinidou, Ioannis S. Vizirianakis   +3 more
wiley   +1 more source

[Acute erythroblastic leukemia presenting as FAB M6 with surface marker positive for megakaryocytic and erythroid: report of a case].

[Rinsho ketsueki] The Japanese journal of clinical hematology, 1994
A fifty five-year-old male presenting as FAB M6 had blasts that were positive both for erythroblastic and megakaryocytic surface makers, i.e., carbonic anhydrase I, CD36 and CD41. HLA-DR and cD71 were also positive. In a very small portion, CD33 and glycophorin A were also positive.
OHATA, Masahiko, SUGIURA, Kousaku, OTSUKA, Syoichi, NONAKA, Kiyoshi, NAKAZAWA, Masaki   +4 more
openaire   +2 more sources